Discover what's new.

Access the latest news, business developments, company updates, industry trends, events and more.

| By Kelley Gipson

Enrich Therapeutics secures funding from CI

Enrich Therapeutics has successfully closed $320k in seed funding. The round was led by Connecticut Innovations. The funding will support the ongoing development of Enrich’s proprietary...

| By Kelley Gipson

Assembly and BeiGene collaborate re hepatitis B

Assembly Biosciences and BeiGene, Ltd. report that the companies have entered into a collaboration in China for Assembly’s portfolio of three clinical-stage core inhibitor candidates...

| By Kelley Gipson

Pfizer, preparing COVID-19 vaccine, has CT presence

Pfizer and BioNTech report the execution of an agreement with the U.S. Department of Health and Human Services and the Department of Defense to begin delivering 300...

| By Kelley Gipson

Pfizer & BioNTech report plans for COVID vaccine

Pfizer and BioNTech report the execution of an agreement with the U.S. Department of Health and Human Services and the Department of Defense to begin delivering 300...

| By Kelley Gipson

BioCT welcomes Aon as Sustaining Sponsor & Partner

It is our pleasure to welcome Aon as BioCT’s newest Sustaining Sponsor and Partner. A leading global professional services firm with a long-standing commitment to...

| By Kelley Gipson

Tweed service to focus on Charlotte, not Philly

American Airlines will cease its longstanding American Eagle daily service between Tweed New Haven Regional Airport and Philadelphia, but expand to twice daily its service...

| By Kelley Gipson

Trevi reports sample size reestimation re pruritus

Trevi Therapeutics has completed the pre-specified sample size re-estimation analysis for the ongoing PRISM Phase 2b/3 trial of Haduvio for severe pruritus in patients with prurigo...

| By Kelley Gipson

NanoViricides closes on $11.5 million stock offering

NanoViricides has completed an underwritten public offering with gross proceeds of $11.5 million. The company is developing antiviral therapies based on a novel nanomedicines platform....

| By Kelley Gipson

New Haven advances 101 College St. project

New Haven’s Board of Alders has thrown its unanimous support behind a $100 million, 10-story bioscience tower in the heart of the city’s downtown. Meeting virtually...